Simcere Pharma (SCR) Misses Street's Q1 Views
Simcere Pharmaceutical Group (NYSE: SCR) reports Q1 EPS of $0.06, 11 cents lower than the analyst estimate of $0.17. Revenue for the quarter was $64.8 million, versus the consensus of $69.87 million.
Related Categories
EarningsStocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
